Smith Group Asset Management’s Neurocrine Biosciences NBIX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-48,114
| Closed | -$6.64M | – | 171 |
|
|
2024
Q1 | $6.64M | Sell |
48,114
-20,340
| -30% | -$2.81M | 0.38% | 70 |
|
|
2023
Q4 | $9.02M | Buy |
+68,454
| New | +$9.02M | 0.52% | 67 |
|
|
2016
Q2 | – | Sell |
-17,720
| Closed | -$701K | – | 506 |
|
|
2016
Q1 | $701K | Sell |
17,720
-150
| -0.8% | -$5.93K | 0.02% | 161 |
|
|
2015
Q4 | $1.01M | Buy |
+17,870
| New | +$1.01M | 0.03% | 173 |
|